Replies to post #3496 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

The litigation passage in the 2022 10-K is not new info; rather, it's a verbatim reiteration of the language in the 2021 10-K:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000147929022000034/rvnc-20211231.htm#id2932a2a7f8d430d9256a3571a3eea70_127